NASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $6.29 +0.05 (+0.80%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.34 +0.05 (+0.81%) As of 08/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arvinas Stock (NASDAQ:ARVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arvinas alerts:Sign Up Key Stats Today's Range$6.09▼$6.2950-Day Range$6.24▼$8.2352-Week Range$5.90▼$29.61Volume2.12 million shsAverage Volume2.07 million shsMarket Capitalization$461.81 millionP/E RatioN/ADividend YieldN/APrice Target$19.76Consensus RatingModerate Buy Company Overview Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Read More Arvinas Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreARVN MarketRank™: Arvinas scored higher than 72% of companies evaluated by MarketBeat, and ranked 284th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arvinas' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Arvinas' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.65% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arvinas has recently increased by 9.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.65% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arvinas has recently increased by 9.37%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.13 News SentimentArvinas has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Arvinas this week, compared to 7 articles on an average week.Search Interest6 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows7 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,377.00 in company stock.Percentage Held by InsidersOnly 4.73% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Stock News HeadlinesArvinas (NASDAQ:ARVN) Given New $18.00 Price Target at HC WainwrightAugust 10 at 2:21 AM | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 9 at 6:38 PM | finance.yahoo.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 10 at 2:00 AM | Paradigm Press (Ad)Oppenheimer Remains a Hold on Arvinas Holding Company (ARVN)August 9 at 5:10 AM | theglobeandmail.comArvinas Holding Company (ARVN) Gets a Buy from GuggenheimAugust 9 at 5:10 AM | theglobeandmail.comWall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious ApproachAugust 8 at 7:09 PM | msn.comArvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call TranscriptAugust 8 at 7:09 PM | msn.comArvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast CancerAugust 8 at 4:05 PM | globenewswire.comSee More Headlines ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $19.17 at the beginning of the year. Since then, ARVN shares have decreased by 67.2% and is now trading at $6.29. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) issued its earnings results on Wednesday, August, 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.03. The firm's revenue was down 70.7% compared to the same quarter last year. Read the conference call transcript. When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. Who are Arvinas' major shareholders? Top institutional investors of Arvinas include Geode Capital Management LLC (2.17%), Acadian Asset Management LLC (1.96%), Monaco Asset Management SAM (1.23%) and Nordea Investment Management AB (0.59%). Insiders that own company stock include John G Houston, Sean A Cassidy, Andrew Saik, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/06/2025Today8/10/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARVN CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees420Year FoundedN/APrice Target and Rating Average Price Target for Arvinas$19.76 High Price Target$55.00 Low Price Target$8.00 Potential Upside/Downside+214.2%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.90 million Net Margins-19.47% Pretax Margin-19.42% Return on Equity-12.01% Return on Assets-6.97% Debt Debt-to-Equity RatioN/A Current Ratio5.64 Quick Ratio4.58 Sales & Book Value Annual Sales$263.40 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value$8.30 per share Price / Book0.76Miscellaneous Outstanding Shares73,420,000Free Float69,945,000Market Cap$461.81 million OptionableOptionable Beta2.22 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ARVN) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.